Description

Ondansetron Solution for Injections 2 mg/ml. 2 ml. Vials №5

Ingredients:

Each 2 ml vial contains 4 mg of Ondansetron (as hydrochloride dihydrate) as the active ingredient.

Dosage:

The usual adult dose is 8 mg administered by slow intravenous injection or infusion, or by intramuscular injection.

Indications:

Ondansetron is indicated for the prevention and treatment of nausea and vomiting induced by chemotherapy, radiotherapy, and postoperative recovery.

Contraindications:

Do not use Ondansetron if you are allergic to it or have a history of severe allergic reactions to it.

Directions:

Administer as directed by a healthcare professional. Do not exceed the recommended dose.

Scientific Evidence:

Ondansetron works by selectively blocking serotonin (5-HT3) receptors, particularly in the chemoreceptor trigger zone, to prevent nausea and vomiting. Studies have shown that Ondansetron is effective in reducing chemotherapy-induced nausea and vomiting, making it a valuable option in cancer treatment regimens.

Research published in the Journal of Clinical Oncology has demonstrated the efficacy of Ondansetron in improving the quality of life for cancer patients undergoing chemotherapy by effectively managing treatment-related nausea and vomiting.

Additional Information:

Ondansetron is well-tolerated with minimal side effects, making it a preferred choice for patients requiring antiemetic therapy. It is considered a first-line treatment for chemotherapy-induced nausea and vomiting due to its proven efficacy and safety profile.

Clinical trials have also shown Ondansetron to be superior to older antiemetics in preventing postoperative nausea and vomiting, highlighting its role in improving patient outcomes and satisfaction following surgical procedures.